Table 1 Baseline characteristics stratified by treatment group.
From: Long-term incidence of posterior capsular opacification in patients with non-infectious uveitis
Treatment group | Acrysof (SN60WF) | iSert XY-1 | iSert 251/255 | Total |
|---|---|---|---|---|
Individuals, N | 90 | 33 | 23 | 146 |
Eyes, N | 124 | 50 | 37 | 211 |
Right | 61 | 25 | 15 | 101 |
Left | 63 | 25 | 22 | 110 |
Age, mean (SD) | 60.0 (13.7) | 62.9 (14.3) | 59.7 (14.6) | 60.7 (14.0) |
Age, range | 20–82 | 36–81 | 28–85 | 20–85 |
Sex, N (%) | ||||
Male | 38 (30.6%) | 15 (30%) | 13 (35.1%) | 66 (30.7%) |
Female | 86 (69.4%) | 35 (70%) | 24 (64.9%) | 145 (69.3%) |
Comorbidity, N (%) | ||||
Diabetes mellitus | 22 (17.7%) | 10 (20%) | 8 (21.6%) | 40 (18.6%) |
Entity N (%) | ||||
Idiopathic uveitis | 71 (57.2%) | 22 (44.0%) | 12 (32.4%) | 105 (49.8%) |
Sarcoidosis | 43 (34.7%) | 19 (38%) | 16 (43.2%) | 78 (36.3%) |
Vogt-Koyanagi-Harada disease | 8 (6.5%) | 0 (0%) | 2 (5.4%) | 10 (4.7%) |
LogMAR, mean (SD) | 1.3 (1.1) | 1.6 (1.2) | 1.1 (1.1) | 1.3 (1.1) |
Refraction, mean (SD) | − 2.0 (2.9) | − 2.3 (2.9) | − 3.3 (3.2) | − 2.3 (3.0) |
